Pharma investing: A good bet?

The folks over at the Motley Fool are wondering if big pharma remains a safe haven in challenging investment times or whether its time for investors to jump ship. Writer Brian Orelli notes that some of big pharma's strongest players were down, but not as down as the Dow and the S&P 500 when the market tanked on Monday. Article

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.